Abstract:BackgroundAlthough immunotherapy can reinvigorate immune cells to clear tumors, the response rates are poor in some patients. Here, CD47 antibody-engineered oncolytic viruses (oAd-αCD47) were employed to lyse tumors and activate immunity. The oAd-αCD47 induced comprehensive remodeling of the tumor microenvironment (TME). However, whether the acidic TME affects the antitumor immunotherapeutic effects of oncolytic viruses-αCD47 has not been clarified.MethodsTo assess the impact of oAd-αCD47 treatment on the TME, we employed multicolor flow cytometry. Glucose uptake was quantified using 2NBDG, while mitochondrial content was evaluated with MitoTracker FM dye. pH imaging of tumors was performed using the pH-sensitive fluorophore SNARF-4F. Moreover, changes in the calmodulin-dependent protein kinase II (CaMKII)/cyclic AMP activates-responsive element-binding proteins (CREB) and peroxisome proliferator-activated receptor gamma coactivator-1α (PGC1α) signaling pathway were confirmed through western blotting and flow cytometry.ResultsHere, we identified sodium bicarbonate (NaBi) as the potent metabolic reprogramming agent that enhanced antitumor responses in the acidic TME. The combination of NaBi and oAd-αCD47 therapy significantly inhibited tumor growth and produced complete immune control in various tumor-bearing mouse models. Mechanistically, combination therapy mainly reduced the number of regulatory T cells and enriched the ratio of M1-type macrophages TAMs (M1.TAMs) to M2-type macrophages TAMs (M2.TAMs), while decreasing the abundance of PD-1+TIM3+expression and increasing the expression of CD107a in the CD8+T cells. Furthermore, the combination therapy enhanced the metabolic function of T cells and macrophages by upregulating PGC1α, a key regulator of mitochondrial biogenesis. This metabolic improvement contributed to a robust antitumor response. Notably, the combination therapy also promoted the generation of memory T cells, suggesting its potential as an effective neoadjuvant treatment for preventing postoperative tumor recurrence and metastasis.ConclusionsTumor acidic microenvironment impairs mitochondrial energy metabolism in macrophages and T cells inducing oAd-αCD47 immunotherapeutic resistance. NaBi improves the acidity of the TME and activates the CaMKII/CREB/PGC1α mitochondrial biosynthesis signaling pathway, which reprograms the energy metabolism of macrophages and T cells in the TME, and oral NaBi enhances the antitumor effect of oAd-αCD47.

Encapsulated Mitochondria to Reprogram the Metabolism of M2-type Macrophages for Anti-Tumor Therapy

Remodeling Tumor-Associated Macrophage for Anti-Cancer Effects by Rational Design of Irreversible Inhibition of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2

Surface Molecularly Engineered Mitochondria Conduct Immunophenotype Repolarization of Tumor-Associated Macrophages to Potentiate Cancer Immunotherapy

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Mir-182 Targeting Reprograms Tumor-Associated Macrophages and Limits Breast Cancer Progression

Self-modifying NanoEnhancers Facilitating Lysosomal Escape for Cgas-Sting Cascading Activation in Tumor Immunotherapy

Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles

Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells

Sequentially Triggered Bacterial Outer Membrane Vesicles for Macrophage Metabolism Modulation and Tumor Metastasis Suppression

Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy

Metabolic Regulating Enhanced Immunological Activating Nanocomposites for Tumor Microenvironment Normalization and Immunotherapy

Mitochondrial Metabolic Reprogramming of Macrophages and T Cells Enhances CD47 Antibody-Engineered Oncolytic Virus Antitumor Immunity

Determining M2 macrophages content for the anti-tumor effects of metal-organic framework-encapsulated pazopanib nanoparticles in breast cancer

Biomimetic O2 Self-generated Hybrid Membrane Nanoplatform for Blocking the Polarization Towards Immunosuppressive M2 Macrophage Phenotype and Enhancing Sonodynamics Therapy in Orthotopic Colorectal Cancer

Combination of Mitochondria Impairment and Inflammation Blockade to Combat Metastasis.

Metabolic Reprogramming by Dual-Targeting Biomimetic Nanoparticles for Enhanced Tumor Chemo-Immunotherapy

pH-sensitive tumor-tropism hybrid membrane-coated nanoparticles for reprogramming the tumor microenvironment and boosting the antitumor immunity

ATP-triggered Mitochondrial Cascade Reactions for Cancer Therapy with Nanoscale Zeolitic Imidazole Framework-90

Biointerface‐Engineered Hybrid Nanovesicles for Targeted Reprogramming of Tumor Microenvironment

Non-cytotoxic nanoparticles re-educating macrophages achieving both innate and adaptive immune responses for tumor therapy

Supramolecular Peptide Amphiphile Nanospheres Reprogram Tumor‐associated Macrophage to Reshape the Immune Microenvironment for Enhanced Breast Cancer Immunotherapy